Bryan Skelton focuses his practice on advising pharmaceutical companies and research institutions on complex legal issues relating to the protection, enforcement and transfer of intellectual property. He has extensive experience in technologies directed to small molecule compounds, compositions and their delivery, and immunology, particularly vaccines and antibodies. His services include counseling clients on developing and implementing patent procurement and reexamination strategies, assisting clients with intellectual property valuations and licensing, conducting due diligence investigations of patent portfolios and preparing opinions on validity, noninfringement and freedom to operate. A significant portion of Bryan’s practice involves conducting due diligence investigations for clients in connection with acquisitions or investment funding. He also advises pharmaceutical and life sciences companies in various IP Litigation matters.

Bryan’s doctoral research in medicinal chemistry focused on designing and synthesizing novel nicotine-based molecules as ligands for nicotinic acetylcholine receptors, which have been implicated in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.